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Abstract
Background: Accurately monitoring adherence to treatment with recombinant human growth hormone (r-hGH)
enables appropriate intervention in cases of poor adherence. The electronic r-hGH auto-injector, easypod™,
automatically records the patient’s adherence to treatment. This study evaluated adherence to treatment of
children who started using the auto-injector and assessed opinions about the device.
Methods: A multicentre, multinational, observational 3-month survey in which children received r-hGH as part of
their normal care. Physicians reviewed the recorded dose history and children (with or without parental assistance)
completed a questionnaire-based survey. Children missing ≤2 injections per month (92% of injections given) were
considered adherent to treatment. Adherence was compared between GH treatment-naïve and treatment-
experienced children.
Results: Of 834 recruited participants, 824 were evaluated. The median (range) age was 11 (1-18) years. From the
recorded dose history, 87.5% of children were adherent to treatment over the 3-month period. Recorded
adherence was higher in treatment-naïve (89.7%, n = 445/496) than in treatment-experienced children (81.7%, n =
152/186) [Fisher’s exact test FI(X) = 7.577; p = 0.0062]. According to self-reported data, 90.2% (607/673) of children
were adherent over 3 months; 51.5% (421/817) missed ≥1 injection over this period (mainly due to forgetfulness).
Concordance between reported and recorded adherence was 84.3%, with a trend towards self-reported adherence
being higher than recorded adherence. Most children liked the auto-injector: over 80% gave the top two
responses from five options for ease of use (720/779), speed (684/805) and comfort (716/804). Although 38.5%
(300/780) of children reported pain on injection, over half of children (210/363) considered the pain to be less or
much less than expected. Given the choice, 91.8% (732/797) of children/parents would continue using the device.
Conclusions: easypod™ provides an accurate method of monitoring adherence to treatment with r-hGH. In
children who received treatment with r-hGH using easypod™, short-term adherence is good, and significantly
higher in treatment-naïve children compared with experienced children. Children/parents rate the device highly.
The high level of acceptability of the device is reflected by a desire to continue using it by over 90% of the
children in the survey.
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Recombinant human growth hormone (r-hGH) is used
to treat growth hormone deficiency (GHD) in adults
and short stature in children [1-3]. Treatment improves
growth in children whose short stature is caused by
GHD, or in those for whom short stature is associated
with conditions such as Turner syndrome (TS), chronic
renal failure (CRF) or being born small for gestational
age (SGA) [1]. Early intervention with long-term r-hGH
treatment improves adult stature, with some patients
reaching target final height. However, lack of adherence
hampers growth potential [4,5].
Maintaining commitment to r-hGH treatment is diffi-
cult, as the short-term burden of injection administra-
tion is often more apparent than the long-term benefits
of therapy [5]. Daily injections or needle-free adminis-
tration is required, and treatment must be sustained
over a prolonged period. Treatment fatigue may have a
negative impact on adherence for patients taking r-hGH
medication on a long-term basis, as suggested by the
observation that chronicity of disease is a factor that
influences adherence to therapy [6]. Studies looking at
adherence to r-hGH treatment have been constrained
by the problem of recording adherence, but results have
shown that non-adherence is a problem in some
patients [4-7]. One UK study highlighted how frequent
poor adherence with r-hGH therapy can be: more than
1 injection/week was missed by 39% (29/75) of children,
whilst 23% (17/75) missed >2 injections/week [5].
The accurate monitoring of adherence rates is impor-
tant as it enables poor adherence to be detected and
acted upon [8]. It can enable the physician to eliminate
poor adherence as a reason for sub-optimal growth
response and be more confident in their patient man-
agement decisions. Innovation in r-hGH delivery devices
has sought to improve adherence by simplifying injec-
tion administration, making it less painful and more
convenient, thereby improving patient acceptability of
devices [9-12]. The electronic auto-injector device, easy-
pod™, has a number of features, such as preset dosing,
an electronic skin sensor and adjustable injection set-
tings, designed to make daily administration of r-hGH
easier, more comfortable and convenient; it also allows
accurate monitoring of treatment adherence [13]. easy-
pod™ has an injection log that automatically records
injection history. This information can be accessed by
patients or downloaded at their clinic to show which
injections, if any, have been missed. Although patient
opinion of the electronic auto-injector has been pre-
viously studied, albeit in a limited number of patients
(n = 61) [14,15], adherence to treatment whilst using
this device has not been explored at all.
We report here the results from the first study of
adherence to treatment as recorded by the auto-injector.
The primary objective of this study was to evaluate
adherence to r-hGH therapy over 3 months of use. In
addition, the survey explored perceptions of the electro-
nic auto-injector device in a large multinational cohort.
Study outcomes were also assessed separately for
children who were either new to or had experience with
r-hGH therapy, in order to identify any differences in
adherence to therapy or opinions of the device.
Methods
Participants
Eligible children were aged ≤18 years and were either
treatment-naïve or already receiving GH treatment, but
dissatisfied with their current self-injection device. All
children had conditions for which treatment with
r-hGH (Saizen
®, Merck Serono S.A. - Geneva, Switzer-
land, an affiliate of Merck KGaA, Darmstadt, Germany)
was indicated, based on local licensing (GHD, TS, CRF
o rS G A ) .C h i l d r e nw e r ee x c l u d e di ft h e yw e r ec u r r e n t l y
participating in a therapeutic trial or had done so in the
preceding 3-month period. Children were also excluded
a ta n yp o i n td u r i n gt h es u r v e yi ft h e yf a i l e dt ob r i n g
their electronic auto-injector to a consultation.
Recruitment took place in 206 centres, across 15
countries, specializing in the management of growth dis-
orders in children.
Study design
This was a multicentre, multinational, observational
study. Treatment with r-hGH was initiated in accor-
dance with the registered dosage regimen for those
new to treatment, or continued as usual for children
already receiving this therapy. No treatment changes
were made. Similarly, no specific procedures, examina-
tions or follow-up visits were required for the survey.
Where applicable, according to local regulations, insti-
tutional approvals and appropriate consents were
obtained. The guardians of the children consented to
the survey.
Objectives
The primary objective was to assess adherence to r-hGH
treatment, following introduction of the electronic
auto-injector, comparing adherence patterns of treat-
ment-naïve and treatment-experienced children. The
secondary objective was to assess the acceptability of the
device.
Outcome measures
Adherence to treatment was measured using data
recorded by the injection device and reported via the
survey. For reported adherence, children or their parents
completed a questionnaire in which they were asked to
tick one of a selection of boxes to indicate how many
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3-month period, and to give the main reason for missing
doses. Recorded adherence data (from the auto-injector)
were compared with reported adherence data (from the
survey).
Acceptance of the electronic auto-injector device was
evaluated using a standardized questionnaire adminis-
tered by the nurse or investigator after 3 months of use
(Table 1). Children or their parents were asked to rate
the device (with respect to ease, speed, comfort of use,
specific device features and future use) using 5-point
scales or multiple-choice responses. The survey was
completed by the child or parent based on each family’s
preference. This information was not collected during
the survey; hence no psychometric properties of the sur-
vey were made available.
Statistical analysis
Sample size
The sample size was based on the primary assessment
criterion of treatment adherence (the definition of treat-
ment adherence used is given below) and the objective
was to demonstrate the equivalence between treatment-
naïve and treatment-experienced children in terms of
treatment adherence. However, as the type of patient
(treatment-naïve or treatment-experienced) recruited
could not be controlled for, there was a bias towards a
greater proportion of treatment-naïve children. It was
therefore decided to perform the statistical analysis in a
descriptive way.
Data analysis
Adherence was evaluated over the 3-month survey per-
iod as a whole and for each month separately to explore
Table 1 Survey questions evaluating acceptability of the electronic auto-injector
Question Response options
How easy do you find the preparation steps of easypod™?1
Very easy
2
Easy
3
Average
4
Not easy
5
Not easy at all
How long does it normally take you to prepare your growth hormone
injection with easypod™?
1
Very short
2
Short
3
Average
4
Long
5
Very long
How long does it normally take you to inject Saizen using easypod™?1
Very short
2
Short
3
Average
4
Long
5
Very long
For each injection site, which setting for the needle insertion depth do you
prefer?
Thighs Low Medium High Not applicable
Belly Low Medium High Not applicable
Buttocks Low Medium High Not applicable
Arms Low Medium High Not applicable
Which setting for the injection speed do you prefer? Low Medium High
Did the injection with easypod™ hurt? Yes No
If yes, did the injection hurt as much as you thought it would? 1
Much less
2
Less
3
Average
4
More
5
Much more
Has easypod™ been easy to use? 1
Very easy
2
Easy
3
Average
4
Not easy
5
Not easy at all
Did you feel comfortable using easypod™?1
Very
comfortable
2
Comfortable
3
Average
4
Not
comfortable
5
Not comfortable
at all
If you had a choice, would you continue to use easypod™? Yes No
Do you think easypod™ is easy to hold/grip? 1
Very easy
2
Easy
3
Average
4
Not easy
5
Not easy at all
Do you think easypod™ is compact/portable? 1
Very
compact
2
Compact
3
Average
4
Not
compact
5
Not compact at
all
Do you think easypod™ has an attractive/nice design? 1
Very
attractive
2
Attractive
3
Average
4
Not
attractive
5
Not attractive at
all
Do you think it is easy to change the cartridge on easypod™?1
Very easy
2
Easy
3
Average
4
Not easy
5
Not easy at all
Do you think it is easy to change the needle on easypod™?1
Very easy
2
Easy
3
Average
4
Not easy
5
Not easy at all
Do you think injection using the easypod™ is quiet? 1
Silent
2
Quiet
3
Average
4
Quite noisy
5
Noisy
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tions prescribed per week was taken into account in the
calculation of adherence. Since adherence is expected to
be high (80-95% [6]) during the first 3 months of treat-
ment, children were considered adherent to treatment if
they received more than 92% of the prescribed doses
over a specified period; i.e. a maximum of two daily
injections missed per month or six daily injections for
the 3-month period.
Three different imputations for missing data were
u s e d .F i r s t ,i ft h en u m b e ro finjections scheduled per
week was not known, the most conservative case sce-
nario (i.e. seven scheduled injections per week) was
assumed. Second, when calculating percentage adher-
ence using the ‘number of missed injections’ question-
naire box selected, the midpoint value for each tick box
was imputed, i.e. when the tick box ‘1-3 injections
missed’ was ticked, the value ‘2’ was imputed.
Third, for data related to the number of doses missed,
the following imputation rule was applied: for respon-
dents answering ‘no’ to the question “did you miss at
least one injection?”, but not completing answers for the
number of injections missed during each of the three 4-
w e e kp e r i o d s ,i tw a sa s s u m e dt h a tt h ef i r s ta n s w e rw a s
correct (i.e. zero injections were missed).
Furthermore, when information on the number of
injections missed per 4-week period was completely
missing, imputation analyses were performed using data
from completed periods.
Analyses of parents’ and children’s device acceptance
were descriptive. However, for the mean adherence
values, 95% confidence intervals were calculated. The
following statistical tests were performed: Fisher’se x a c t
test was used to compare adherence between treatment-
naïve and treatment-experienced children and the
Wilcoxon signed rank test was used to compare
recorded adherence and reported adherence. The signifi-
cance level of the tests was set at 5%.
Results
Participants
Overall, 834 children using the electronic auto-injector
were recruited over a period of 1.5 years. Of these, 824
children were included in the evaluable population, with
four children excluded due to incomplete data (age
missing [n = 1], status missing [n = 3]) and six children
excluded due to being aged >18 years. Of the 824 evalu-
able children, 601 were treatment-naïve and 223 were
treatment-experienced. In total, 682/824 (82.8%) chil-
dren provided 3 months of data: 496/601 (82.5%) of
treatment-naïve children and 186/223 (83.4%) of treat-
ment-experienced children. The remaining children had
incomplete information for the numbers of reported and
recorded injections.
The 824 children were recruited from 206 centres
across 15 countries. The number of children recruited
from each country is shown in Figure 1. Characteristics
of the survey population are shown in Table 2. Parents
administered the injections for 52.8% (430/815) of chil-
dren. The median (range) age of children administering
their own injections was 13 (5-18) years and for children
whose parents took control of injections was 9 (1-18)
years. Most children (564/798; 70.7%) were prescribed
seven injections per week, with the remaining children
prescribed only six injections per week.
Recorded adherence
Looking at the recorded dose history for only those chil-
dren who provided complete data sets, 87.5% of children
met the criteria for adherence to treatment over the
3-month period. Adherence was significantly higher in
treatment-naïve children (89.7%) than in treatment-
experienced children (81.7%; Fisher’s exact test FI(X) =
7.577; p = 0.0062) (Table 3a). There was little change in
the proportion of children reaching the adherence cri-
terion over the 3 months (90.5% in month 1, 87.1% in
month 2 and 88.9% in month 3) (Table 3b).
Over the 3-month period, there was a slight, non-
significant difference in the proportion of children
adherent to treatment according to who administered
the injections: 84.8% in all children for whom their
parents administered the injections versus 82.7% in all
children who administered the injections themselves
(using imputed data). This trend was driven by adher-
ence data from month 3, as adherence was similar
during months 1 and 2.
Over the whole 3-month period, 51.4% (397/772) of
children were recorded to have missed one or more
injections. There was a gradual increase in the number
of children missing injections from one month to the
next (Figure 2). In month 1, 75.1% (535/712) of children
were recorded as missing no injections, in month 2,
66.7% (481/721), and in month 3, 66.7% (480/720). The
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Figure 1 Geographic distribution of survey participants in the
evaluable population.
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Page 4 of 10number of children missing 1-3 injections per month
increased over the same period (from 18.5% [132/712]
to 24.4% [176/720]). Few children missed >10 injections:
only 3.1% (22/720) in month 3.
The mean recorded adherence was also assessed for
individual countries (only in countries for which data
were available for >50 children). Of these countries,
overall recorded adherence was greatest in Spain (96.9%)
and lowest in Argentina (75.4%; Figure 3). Adherence
was higher for treatment-naïve children than treatment-
experienced children in all countries with the exception
o ft h eN o r d i cc o u n t r i e s( F i n l a n d ,N o r w a ya n dS w e d e n ) ,
Portugal and Spain, for which adherence was more com-
parable between the two patient types (Figure 3).
Table 2 Characteristics of the evaluable survey population
Total
(N = 824)
Treatment-naïve
(n = 601)
Treatment-experienced
(n = 223)
Boys, n (%)
a 462 (56.1) 358 (59.6) 104 (46.9)
Age, median (range), years 11 (1-18) 11 (1-18) 11 (2-18)
Indication, n (%)
b
GHD 543 (66.4) 407 (68.1) 136 (61.8)
TS 80 (9.8) 46 (7.7) 34 (15.5)
CRF 14 (1.7) 10 (1.7) 4 (1.8)
SGA 125 (15.3) 98 (16.4) 27 (12.3)
Other 56 (6.8) 37 (6.2) 19 (8.6)
Administration of injections
c
Child 315 (38.7) 224 (37.5) 91 (41.7)
Parent 430 (52.8) 317 (53.1) 113 (51.8)
Other 7 (0.86) 6 (1.01) 1 (0.46)
Child and parent 59 (7.2) 46 (7.7) 13 (6.0)
Parent and other 4 (0.49) 4 (0.67) 0
Number of scheduled injections per week
d
6 234 (29.3) 177 (30.2) 57 (26.9)
7 564 (70.7) 409 (69.8) 155 (73.1)
aOne child missing from the treatment-experienced group.
bSix children missing: three each from the treatment-naïve and treatment-experienced groups.
CNine children missing: four from the treatment-naïve group and five from the treatment-experienced group.
dTwenty-six children missing: fifteen from the treatment-naïve group and eleven from the treatment-experienced group.
CRF – chronic renal failure; GHD – growth hormone deficiency; SGA – small for gestational age; TS – Turner syndrome.
Table 3 Adherence to treatment ( > 92% of injections taken)
Total
(N = 824)
Treatment-naïve
(n = 601)
Treatment-experienced
(n = 223)
(a)
Recorded adherence - all children
Overall, n (%)* 649/772 (84.1) 484/561 (86.3) 165/211 (78.2)
Recorded adherence - children who provided 3 months of data
Overall, n (%) 597/682 (87.5) 445/496 (89.7) 152/186 (81.7)
Reported adherence - all children
Overall, n (%)* 677/790 (85.7) 497/573 (86.7) 180/217 (83.0)
Reported adherence - children who provided 3 months of data
Overall, n (%) 607/673 (90.2) 447/489 (91.4) 160/184 (87.0)
(b)
Recorded adherence - children who provided 3 months of data
Month 1, n (%) 617/682 (90.5) 458/496 (92.3) 159/186 (85.5)
Month 2, n (%) 594/682 (87.1) 441/496 (88.9) 153/186 (82.3)
Month 3, n (%) 606/682 (88.9) 449/496 (90.5) 157/186 (84.4)
(a) Adherence as recorded and reported by children/parents overall over the 3-month survey. (b) Adherence as recorded by easypod™ over each month of the
3-month survey.
*Overall adherence calculated by imputation of missing period(s) using non-missing period(s).
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The self-reported adherence results indicated that 90.2%
of children were adherent to treatment over the 3-
month period (Table 3a). Using the self-reported survey
data, 51.5% (421/817) of children were reported to have
missed ≥1 injection over the 3-month period. The most
common reason (given by 43.7% of eligible respondents)
for missing a dose was forgetfulness; other reasons
(cited by >10% of eligible respondents) included the
device not working, running out of cartridges/needles
and being away from home (Table 4).
Recorded versus reported adherence
Comparing recorded against reported adherence showed
that more children had higher reported adherence than
recorded adherence at each time point as well as overall
(90.2% vs 87.5%; Table 3a). An assessment of difference
and concordance between reported and recorded adher-
ence revealed that over months 1-3, the recorded and
reported adherence values were equal for 84.3% of all
children, but in 16% of children, reported adherence
values were different to recorded adherence values:
reported adherence was higher than recorded adherence
for 12.8% of children and recorded adherence was
higher than reported for 3.0% (mean percentage differ-
ence between recorded and reported adherence -0.85;
p < 0.0001 using the signed rank test). Similar trends
were observed in treatment-naïve and treatment-
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naires were being administered prospectively and retro-
spectively; however, an exploratory analysis showed no
differences in adherence between the two approaches
were observed.
Acceptability of the electronic auto-injector device
Device preparation
Overall, 82.5% (664/805) of participants found the elec-
tronic auto-injector easy/very easy to prepare. Only 2.2%
(18/805) of respondents rated the injection preparation
as not easy at all (Table 5). The majority (684/806,
84.9%) of respondents also rated the duration of injec-
tion preparation as short/very short (Table 5).
Device use
When questioned about the ease and duration of injec-
tion, 92.4% (720/779) of respondents said that it was
easy/very easy to use and 85.0% (684/805) rated the
duration of injection as short/very short (Table 5).
Of the possible choices for injection location (thighs,
belly, buttocks or arms), the thighs were the preferred
site (88.3% [686/777] of children injected in the thighs,
whereas other sites were used by less than 53.8%). Over-
all, the default setting (medium) was preferred for both
injection depth (72.3% [562/777] when injecting in the
thighs; 35.7% [231/647] when injecting in the belly; 41.9%
[279/666] when injecting in the buttocks; and 43.5%
[285/656] when injecting in the arms) and injection
speed (71.1% [566/796] when injecting in any location).
The device was described by 89.1% (716/804) of partici-
pants as comfortable/very comfortable to use (Table 5).
The majority of respondents (61.5% [480/780]) reported
experiencing no pain when injecting with the electronic
auto-injector. Those patients who experienced pain were
Table 4 Most common reasons given for missed injections
Total
(n = 412)
Treatment-naïve
(n = 296)
Treatment-experienced
(n = 116)
Forgot injection 180 (43.7) 135 (45.6) 45 (38.8)
Device not working 75 (18.2) 54 (18.2) 21 (18.1)
Short vacations, slept away from home 52 (12.6) 31 (10.5) 21 (18.1)
Ran out of cartridges/needles 53 (12.9) 43 (14.5) 10 (8.6)
Forgot drug/easypod™ 32 (7.8) 25 (8.5) 7 (6.0)
Sick 35 (8.5) 23 (7.8) 12 (10.3)
Afraid of using easypod™ 12 (2.9) 5 (1.7) 7 (6.0)
Tired of injections 18 (4.4) 7 (2.4) 11 (9.5)
Reconstitution issues 13 (3.2) 11 (3.7) 2 (1.7)
Lack of caregiver to provide injection 5 (1.2) 3 (1.0) 2 (1.7)
Too complicated/forgot how to use device 4 (0.97) 2 (0.68) 2 (1.7)
Other 11 (2.7) 6 (2.0) 5 (4.3)
Data values represent number (percentage) of respondents who gave the indicated response as a reason for missing injections.
Table 5 Acceptance of the electronic auto-injector
Number
of
respondents
Most
positive
answer
® Least
positive
answer
1 234 5
Device preparation Ease 805 53.5 28.9 12.6 2.7 2.2
Duration 806 53.2 31.6 12.7 0.99 1.5
Device use Ease 779 62.6 29.8 5.8 1.0 0.77
Duration 805 53.0 31.9 13.3 1.2 0.50
Comfort 804 57.5 31.6 7.6 1.7 1.6
Device features Grip 813 59.7 28.2 9.0 2.1 1.1
Size 803 52.4 26.0 15.6 3.6 2.4
Attractiveness 807 56.6 28.3 12.8 1.5 0.87
Ease of cartridge change 801 58.8 27.0 10.4 2.9 1.0
Ease of needle change 809 56.9 26.1 12.2 3.7 1.1
Noise 807 51.7 32.3 12.1 2.6 1.2
Figures indicate the percentage of survey participants giving the indicated rating (scale of 1-5) in response to specific questions about the electronic auto-
injector.
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were expecting (although this question was also answered
by some of those who said that they did not experience
pain). Over half (57.9% [210/363]) of respondents to this
question described it as being less or much less painful
than expected. Few respondents (13.5% [49/363])
reported that the injection hurt more/much more than
they thought it would.
Device features
Survey participants were also asked to answer questions
concerning specific features of the electronic auto-injec-
tor. In total, 85.8% (687/801) and 82.9% (671/809) stated
that the cartridge and needle, respectively, were easy/
very easy to change (Table 5). Most participants found
the device easy to hold and compact, as well as attrac-
tive and silent/quiet on injection (Table 5).
Future use of the device
At the end of the 3-month survey period, 91.8% (732/
797) of respondents stated a desire to continue using
the electronic auto-injector: 92.7% (542/585) of treat-
ment-naïve and 89.6% (190/212) of treatment-experi-
enced children.
For children who did not want to continue using the
device, 74.6% (44/59) were recorded as being adherent
to treatment.
Discussion
This multinational, observational survey of over 800
children using an electronic auto-injector device for up
to 3 months found a good level of adherence to therapy.
The dose history that had been automatically recorded
by the device and reviewed by the physician showed
that 87.5% of children were adherent to therapy (inject-
ing at least 92% of doses over the 3-month period).
Furthermore, 75.1% of all children did not miss any
injections in month 1, 66.7% in both months 2 and 3.
Adherence to treatment has an important impact on
overall treatment outcome. In a group of poorly compli-
ant patients, growth rates were found to be significantly
lower compared with patients who missed fewer doses
[4]: height velocity in patients missing >15 injections per
month (equivalent to >3-4 per week) was 6.3 cm/year
compared with 9.4 cm/year in those missing 11-15
doses per month (p < 0.03). It has also been estimated
that growth velocity suffers a significant decline if >2
injections per week are missed [5]. In this survey, it was
possible to monitor how many injections were missed
during each month of the survey by looking at the dose-
history data from the electronic auto-injector. By scaling
up to find a comparable figure for the proportion of
patients who missed >2 injections per week, only a rela-
tively small percentage of children had a level of non-
adherence that would have a serious impact on growth
(< 5% of children missed ≥7 injections in month 3).
Adherence was higher in treatment-naïve children
compared with treatment-experienced children (89.7%
vs 81.7%) over the course of the survey. This observa-
tion suggests that a drop in adherence may occur with
increasing duration of treatment: longer-term users may
be less enthusiastic or motivated about adhering to
treatment compared with those users new to treatment,
who may be more diligent. This agrees with previous
studies with GH [5] and other therapies taken on a
long-term basis [16,17]. Even within the short duration
of the survey, a moderate decline in adherence rates was
observed. The very good levels of recorded adherence
during the first month, when 75.1% of children missed
no injections, fell in the second and third months, with
66.7% of children missing no injections at month 3. As
this survey only followed children for 3 months, an eva-
luation of adherence over a longer time period is cur-
rently planned.
Self-reported adherence, collected via the survey,
showed slightly higher rates of adherence than the dose-
history data (90.2% vs 87.5%). Although asking the user
about their injection habits may be the most straightfor-
ward approach to evaluating adherence, these results
show that it may not always be a reliable and accurate
method. Missed doses may be forgotten and adherence
overestimated. Electronic recording of the dosing history
using a device with an integrated dose log offers an
improved, objective method of accurately monitoring
adherence.
The rates of compliance reported here compare well
with previous studies [4,5]. Data from an American GH
registry based on physician-reported adherence, indicate
that 76-85% missed 0-3 doses per month, over a 24-
month period [4]. In the current survey, a child was
considered adherent to treatment if they missed a maxi-
mum of two injections per month. Therefore, a propor-
tion of the children considered adherent in the
American GH registry (those who missed three injec-
tions per month) will not have been considered adher-
ent in our study. In a study of 75 children attending a
UK clinic, an assessment of adherence was based on
prescriptions over 12 months [5]. The frequency of
missed injections was estimated to be 0 in 36% of chil-
dren, up to 1 per week in 25% of children, >1-2 per
week in 16% of children and >2 per week in 23% of
children.
Although the factors influencing adherence and persis-
tence in GH treatment were not explored here, misper-
ceptions about the consequences of missed GH doses,
discomfort with injections, dissatisfaction with treatment
results and inadequate contact with healthcare providers
are among the key reasons reported in other studies
[6,7]. Coaching by healthcare professionals and ongoing
discussions about the benefits of treatment are
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autonomy in managing their own condition is also pre-
dictive of treatment adherence, as is involving the
patient in treatment decisions [19]. Patients may be
more likely to be adherent to treatment if they are
allowed to choose the delivery device [5,20]. Potential
barriers to better adherence include the use of compli-
cated delivery devices [18], suggesting that having a
good perception of the delivery device is a factor that
may also influence adherence.
The current survey also showed that children and
their parents had a very good perception of the electro-
nic auto-injector after 3 months of use, rating specific
features of the device highly. The majority considered
t h ed e v i c et ob eq u i c k ,e a s ya n dc o m f o r t a b l et ou s e .
There was little difference between treatment-naïve and
treatment-experienced children in their responses to
questions.
These results support the findings of previous, smaller
(up to 61 patients), shorter-term (up to 60 days) studies,
which together indicate a high level of patient accep-
tance of the electronic auto-injector for daily adminis-
tration of r-hGH [14,15]. Results from an open-label
multicentre survey that included 61 patients showed
that the majority of patients had a good overall impres-
sion of the device after 60 days of use [14]. In addition,
the nurses/physicians who trained them how to use the
device also rated the device favourably with respect to
participants’ ease in learning to use the device [14].
Unlike previous user trials of the electronic auto-injector
[14,15], the current study is the first to include data on
adherence as captured using the device.
In a survey conducted at a UK hospital, patients com-
mencing GH therapy were given the freedom to choose
their delivery device [20]. Of those switching devices,
74% changed to the electronic auto-injector. None of
the patients who started on this novel device later
switched to using another device. Although the present
survey did not provide children or their parents with a
free choice of injection device, at the end of the survey,
92% of children/parents stated that they would like to
continue using it. Interestingly, adherence in children
w h od i dn o tw a n tt oc o n t i n u eu s i n gt h ed e v i c ew a s
slightly lower than that in the overall population (when
considering all children in the evaluable population,
74.6% vs 84.1%, respectively).
Conclusions
This survey of 824 children showed a high level of compli-
ance to daily r-hGH administration using easypod™ over
a 3-month period, with almost 90% of children meeting
the criterion for adherence to treatment. A significantly
higher adherence rate was observed in treatment-naïve
children compared with treatment-experienced children.
In addition, children/parents liked the device and found it
easy to use for daily administration of r-hGH even if they
did not have any previous experience of injecting. More-
over, almost all wanted to continue using it. Such accep-
tance of devices for r-hGH administration should reduce
the burden of daily treatment and may improve adherence
to therapy. Good adherence, as demonstrated here, should
lead to optimal efficacy and allow children to reach their
height potential.
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